CeriBell (CBLL) Stock Price, News & Analysis

Company Overview

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows. CeriBell devices typically feature automated test protocols, digital signal processing and connectivity options for integration with electronic health record systems. These diagnostic platforms are engineered to meet regulatory requirements in multiple jurisdictions and are complemented by service contracts and technical support offerings.

CeriBell has developed a global presence through direct sales and distribution partnerships across North America, Europe and select international markets. By collaborating with healthcare providers, clinical laboratories and research institutions, the company focuses on refining screening protocols, delivering training resources and expanding access to early hearing assessment solutions. CeriBell’s commitment to innovation and clinical validation underpins its mission to reduce the incidence of undiagnosed hearing loss in newborns and support positive developmental outcomes in pediatric populations.

Key Stats

• Today's Range: $19.82 to $20.55
• 50-Day Range: $17.54 to $21.33
• 52-Week Range: $10.85 to $24.33
• Volume: 109,778 shs
• Average Volume: 304,821 shs
• Market Capitalization: $767.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.20
• Consensus Rating: Moderate Buy

CeriBell Stock Analysis - MarketRank™

CeriBell scored higher than 44% of companies evaluated by MarketBeat, and ranked 523rd out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CeriBell has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

CeriBell has a consensus price target of $23.20, representing about 16.0% upside from its current price of $20.01.

Amount of Analyst Coverage

CeriBell has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CeriBell are expected to grow in the coming year, from ($1.44) to ($0.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CeriBell is -13.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CeriBell is -13.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CeriBell has a P/B Ratio of 4.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.06% of the float of CeriBell has been sold short.

Short Interest Ratio / Days to Cover

CeriBell has a short interest ratio ("days to cover") of 6.13.

Change versus previous month

Short interest in CeriBell has recently decreased by 18.62%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CeriBell does not currently pay a dividend.

Dividend Growth

CeriBell does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.18

News Sentiment

CeriBell has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for CeriBell this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added CeriBell to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, CeriBell insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,310,772.00 in company stock.

Percentage Held by Insiders

20.10% of the stock of CeriBell is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

CeriBell has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 2/24/2026
• Today: 5/08/2026
• Next Earnings (Estimated): 5/11/2026
• Bank of America Global Healthcare Conference 2026: 5/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CBLL
• Previous Symbol: NASDAQ:CBLL
• CIK: 1861107
• Web: N/A
• Phone: (800) 436-0826
• Fax: N/A
• Employees: N/A
• Year Founded: 2014

Price Target and Rating

• Average Price Target for CeriBell: $23.20
• High Price Target: $30.00
• Low Price Target: $17.00
• Potential Upside/Downside: +14.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$53.41 million
• Net Margins: -59.97%
• Pretax Margin: -59.97%
• Return on Equity: -31.77%
• Return on Assets: -26.17%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 9.73
• Quick Ratio: 9.35

Sales & Book Value

• Annual Sales: $89.06 million
• Price / Sales: 8.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.19 per share
• Price / Book: 4.84

Miscellaneous

• Outstanding Shares: 37,872,000
• Free Float: 30,260,000
• Market Cap: $768.08 million
• Optionable: N/A
• Beta: 0.99